Compare Nippon India Pharma Fund vs UTI Healthcare Fund
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.82 | 2.26 |
NAV | ₹506.37 | ₹282.26 |
Fund Started | 10 May 2004 | 01 Aug 2005 |
Fund Size | ₹8458.68 Cr | ₹1126.13 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
3.0
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.82
2.26
NAV
₹506.37
₹282.26
Fund Started
10 May 2004
01 Aug 2005
Fund Size
₹8458.68 Cr
₹1126.13 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1% if redeemed within 30 days.
1 Year | -2.63% | -3.06% |
3 Year | 21.34% | 23.81% |
5 Year | 14.99% | 14.77% |
1 Year
-2.63%
-3.06%
3 Year
21.34%
23.81%
5 Year
14.99%
14.77%
Equity | 99.47% | 98.75% |
Cash | 0.53% | 1.24% |
Equity
99.47%
98.75%
Cash
0.53%
1.24%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 13.55% |
Lupin Ltd. | 7.59% |
Divi's Laboratories Ltd. | 6.90% |
Cipla Ltd. | 6.33% |
Dr. Reddy's Laboratories Ltd. | 5.83% |
Apollo Hospitals Enterprise Ltd. | 5.63% |
Medplus Health Services Ltd. | 3.47% |
Vijaya Diagnostic Centre Ltd. | 3.41% |
Ajanta Pharma Ltd. | 2.90% |
Glaxosmithkline Pharmaceuticals Ltd. | 2.77% |
Sun Pharmaceutical Industries Ltd. | 9.76% |
Ajanta Pharma Ltd. | 6.48% |
Lupin Ltd. | 5.91% |
Glenmark Pharmaceuticals Ltd. | 4.06% |
Dr. Reddy's Laboratories Ltd. | 3.74% |
Gland Pharma Ltd. | 3.46% |
Apollo Hospitals Enterprise Ltd. | 3.45% |
Alkem Laboratories Ltd. | 3.43% |
Procter & Gamble Health Ltd. | 3.41% |
Cipla Ltd. | 3.40% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 10 May 2004 | 01 Aug 2005 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
10 May 2004
01 Aug 2005